In addition, six patients were molecularly diagnosed with chronic mucocutaneous candidiasis (CMC) or chronic granulomatous disease (CGD), which can be treated with ruxolitinib (CMC) or IFN-γ (CGD) [46, 62]. The gene discussed is IFNG; the disease is chronic granulomatous disease.